Translational Scientist
As a translational scientist, you play a pivotal role in bridging the gap between preclinical findings and clinical applications. Our platform is designed to help you decode disease mechanisms, reconcile disparate research findings, predict potential clinical outcomes, and design effective translational strategies with ease and precision. With Causaly, uncover intricate disease-pathway correlations, identify promising therapeutic targets, and generate actionable insights faster than ever before. Join us in accelerating therapy development and innovating therapeutic translation, driving the future of translational medicine and contributing to breakthroughs in life sciences.
Target & Disease Biology
Use AI to uncover hidden mechanistic connections in the literature.
Comprehensive Analysis
Investigate the vast biomedical literature, enriching your understanding of target and disease biology.
Novel Insight Discovery
Uncover hidden relationships and connections, revealing new insights into disease mechanisms and potential therapeutic targets.
Efficiency Enhancement
Navigate through immense biomedical data swiftly, accelerating your study of disease and target biology.
Reconcile Evidence
Get a balanced view of the evidence, forming robust hypotheses.
Contradiction Resolution
Navigate efficiently through extensive biomedical literature, resolving contradictory evidence and enhancing their understanding of the research landscape.
Accuracy Assurance
Cross-verify research findings from various studies, minimizing the likelihood of erroneous conclusions due to conflicting evidence.
Theory Strengthening
Refine and bolster your theories by systematically addressing contradictory evidence, leading to stronger and more valid conclusions.
Design Preclinical Studies
Use historical insights to design and validate current experiments, including animal model selection.
Study Planning
Design comprehensive preclinical studies, using a vast literature analysis to identify critical factors and anticipate potential outcomes.
Hypothesis Enhancement
Strengthen your hypotheses with the aid of extensive prior research, leading to the formulation of robust and targeted preclinical study designs.
Risk Management
Predict potential challenges and devise strategies to avoid them, thereby enhancing the reliability and success rate of your preclinical studies.
Develop Efficacious Trials
Understand which patient subgroups are likely to respond and develop biomarker strategies to identify and stratify patients.
Safety Evaluation
Identify potential safety concerns early on by comprehensively analyzing biomedical literature, aiding in the design of safer clinical trials.
Efficacy Assessment
Develop a thorough understanding of therapeutic profiles, informing the design of more efficacious clinical trials.
Trial Optimization
Refine clinical trial designs by understanding potential risks and incorporating this knowledge, improving overall trial safety and efficacy.
Streamline Translation
Contribute more reliable and impactful results to the field, leading to improved patient outcomes.
Accelerated Translation
Analyze vast amounts of biomedical literature swiftly, accelerating the transition from preclinical findings to clinical applications.
Focused Research
Gain clearer direction for your research, cutting through the noise in the literature to focus on the most promising areas of translation.
Efficiency Boost
Validate or refute your hypotheses rapidly, streamlining your research process and accelerating the overall translation timeline.
Target & Disease Biology
Use AI to uncover hidden mechanistic connections in the literature.Comprehensive Analysis
Investigate the vast biomedical literature, enriching your understanding of target and disease biology.
Novel Insight Discovery
Uncover hidden relationships and connections, revealing new insights into disease mechanisms and potential therapeutic targets.
Efficiency Enhancement
Navigate through immense biomedical data swiftly, accelerating your study of disease and target biology.
Translational Scientist Resources
View More
Biomarkers of Survival for Duchenne Muscular Dystrophy
DMD is a fatal disease with no cure. Identifying biomarkers linked to DMD patient survival is vital for understanding disease progression, evaluating treatment effectiveness, and enhancing outcomes for those with this rare disease.
Identifying Biomarkers of Crohn’s Disease: IL23
Inflammatory Bowel Disease (IBD) affects millions of people worldwide. In Crohn’s disease, one of the main forms of IBD, biomarkers are pivotal for diagnosis and treatment guidance.
BDNF as a Biomarker for Spinocerebellar Ataxia
Spinocerebellar ataxia is a neurodegenerative disease, affecting 1 to 5 people per 100,000. The identification of biomarkers can provide key insights into the state and progression of a disease, in addition to patient response to treatments. As such, biomarkers can improve the success rates of drug development, accelerating the availability of new therapeutics.
Identifying Blood Biomarkers of Atherosclerosis
Atherosclerosis is one of the leading causes of death worldwide. Biomarkers play a crucial role in comprehending atherosclerosis, providing measurable indicators of disease presence, progression, and treatment response.
Hormone Biomarkers for Alzheimer’s Disease: Corticosterone vs. Cortisol
Alzheimer’s disease (AD) is the most prevalent form of dementia. An estimated 6.5 million Americans aged 65 and older are living with Alzheimer’s dementia, a figure which is projected to soar to around 14 million by 2060. Current treatments only offer temporary symptomatic relief, highlighting the importance of AD research.
Exploring Biomarkers for Sickle Cell Disease
Since the 1950s, more than 500 biomarkers for SCD have been reported in the literature, according to Causaly data. Comparing this to more common blood diseases such as leukemia, which has over 10x more biomarkers reported, highlights the significant unmet need in the rare disease research.
Insights from our talk at Biomarkers 2023: The use of human-centric AI in biomarker identification in Oncology and Immunology
Biomarkers 2023 was held in Manchester, UK on the 27th and 28th of February. The event brought together a diverse group of experts, across pharma, biotech, and academic institutions.
Why poor target validation is costing pharmaceutical businesses millions
It has been well documented that only 1 out of 10 compounds that enter clinical trials makes it to market¹. That is an astonishing 90% failure rate. It is hard to imagine hiring a lawyer or doctor or any professional who fails so often. Yet in our industry, it remains the norm.